EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection

Antoine Froment iD, Julia Delomez, Sophie Da Nascimento, Alexandra Dassonville-Klimpt, Claire Andréjak, François Peltier, Cédric Joseph, Pascal Sonnet, Jean-Philippe Lanoix

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Antoine Froment und 8 weiteren Autor:innen. Beteiligte Einrichtung: AGIR UR-4294, Université de Picardie Jules Verne, Amiens, France. Hauptthemen laut MEDLINE: Mefloquine, Mice, Inbred BALB C, Disease Models, Animal, Mycobacterium avium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comité Départemental De Lutte Contre Les Maladies Respiratoires.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of Mycobacterium avium infections is still long, complex, and often poorly tolerated, besides emergence of resistances. New active molecules that are more effective and better tolerated are deeply needed. Mefloquine and its enantiomers ((+) Erythro-mefloquine ((+)-EMQ) and (-)-Erythro-mefloquine ((-)-EMQ)) have shown efficacy in both in vitro and in vivo , in a mouse model of M . avium intraveinous infection. However, no study reports aerosol model of infection or combination with gold standard treatment. That was the aim of our study. In an aerosol model of M . avium infection in BALB/c mice, we used five treatment groups as followed: Clarithromycin-Ethambutol-Rifampicin (CLR-EMB-RIF, standard of care, n = 15), CLR-EMB-MFQ (n = 15), CLR-EMB-(+)-EMQ (n = 15), CLR-EMB-(-)-EMQ (n = 15) and an untreated group (n = 25). To evaluate drug efficacy, we sacrificed each month over 3 months, 5 mice from each group. Lung homogenates were diluted and plated for colony forming unit count (CFU) expressed in Log10. At each time point, we found a significant difference between the untreated group and each of the treatment groups (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MefloquineMice, Inbred BALB CDisease Models, AnimalMycobacterium aviumAnimalsMiceStereoisomerismFemaleRifampinClarithromycinAntitubercular AgentsEthambutolDrug Therapy, CombinationTuberculosisLung

Substanzen

MefloquineRifampinClarithromycinAntitubercular AgentsEthambutol

Autor:innen und Institutionen

  • AGIR UR-4294, Université de Picardie Jules Verne, Amiens, France.
  • Infectious Disease Department, Amiens-Picardie University Hospital, Amiens, France.
  • Pneumology Department, Amiens-Picardie University Hospital, Amiens, France.

ORCID-Profile: Antoine Froment

Förderung

  • Comité Départemental De Lutte Contre Les Maladies Respiratoires

Zitieren

APA

Froment, A., Delomez, J., Da Nascimento, S., Dassonville-Klimpt, A., Andréjak, C., Peltier, F., Joseph, C., Sonnet, P., & Lanoix, J. P. (2024). Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection. PLOS ONE. https://doi.org/10.1371/journal.pone.0311167

Vancouver

Froment A, Delomez J, Da Nascimento S, Dassonville-Klimpt A, Andréjak C, Peltier F, et al. Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection. PLOS ONE. 2024. doi:10.1371/journal.pone.0311167

BibTeX
@article{Froment2024,
  author = {Froment, Antoine and Delomez, Julia and Da Nascimento, Sophie and Dassonville-Klimpt, Alexandra and Andréjak, Claire and Peltier, François and Joseph, Cédric and Sonnet, Pascal and Lanoix, Jean-Philippe},
  title = {Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311167}
}
Kostenlos starten →